Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2019
2020
2022
2023
2024
2025
GT Biopharma, Inc. (GTBP)
Price$0.2307Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | $0 | $0 | — | $0 | $0 | $27,000 | $61,000 | $368,000 | $342,000 | $26,000 | $11,000 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 | $27,000 | $4,000 | $142,000 | $248,000 | −$22,000 | −$54,000 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | 100.00% | 6.56% | 38.59% | 72.51% | −84.62% | −490.91% |
| Research & development | $3.5M | $5.8M | $2.1M | $8.8M | $9.6M | $485,000 | $1.7M | $9.1M | $1.1M | $975,000 | $1.0M | $0 | $0 | $0 | $17,000 | $179,000 |
| Operating expenses | $12.4M | $14.4M | $13.6M | $21.3M | $57.5M | — | $16.1M | $250.1M | $135.6M | $9.4M | $9.0M | $2.4M | $935,000 | $3.8M | $3.9M | $2.4M |
| Operating income | −$12.4M | −$14.4M | −$13.6M | −$21.3M | −$57.5M | −$6.8M | $16.1M | −$250.1M | −$135.6M | −$9.4M | −$8.9M | −$2.4M | −$793,000 | −$3.5M | −$3.9M | −$2.5M |
| Operating margin | — | — | — | — | — | — | — | — | — | — | −33,062.96% | −3,927.87% | −215.49% | −1,027.49% | −15,107.69% | −22,700.00% |
| EBITDA | −$28.2M | −$13.2M | −$7.4M | −$20.9M | — | −$6.8M | $16.1M | −$250.1M | −$135.6M | −$9.4M | −$8.9M | −$2.4M | — | — | — | — |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — | −33,055.56% | −3,891.80% | — | — | — | — |
| Net income | −$28.4M | −$13.2M | −$7.6M | −$20.9M | −$58.0M | −$28.3M | −$38.6M | −$259.2M | −$144.2M | $9.8M | −$21.5M | −$23.5M | −$501,000 | −$5.2M | −$3.7M | −$3.0M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | −79,485.19% | −38,506.56% | −136.14% | −1,511.99% | −14,230.77% | −27,227.27% |
| Basic EPSper basic share | -$6.68 | -$6.94 | -$5.64 | -$19.66 | -$61.80 | -$193.50 | -$0.30 | -$2,631.60 | -$4,386.00 | $61,154.10 | -$4,569.60 | -$20.40 | -$5.10 | -$5.10 | -$10.20 | -$15.30 |
| Diluted EPSper diluted share | -$6.68 | -$6.94 | -$5.64 | -$19.66 | -$61.80 | -$193.50 | -$0.30 | -$2,631.60 | -$4,386.00 | $61,154.10 | -$4,569.60 | -$20.40 | -$5.10 | -$5.10 | -$10.20 | -$15.30 |
Owners
Reported shareholders
0.84%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC376.4K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 0.84%376.4K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.60%266.79K shares |
VANGUARD FIDUCIARY TRUST CO | 0.51%225.94K shares |
HRT FINANCIAL LP | 0.24%107.14K shares |
Everhart Financial Group, Inc. | 0.22%100K shares |
Arax Advisory Partners | 0.21%93.63K shares |
Opal Wealth Advisors, LLC | 0.18%81.81K shares |
NORTHERN TRUST CORP | 0.17%75.46K shares |
49 WEALTH MANAGEMENT, LLC | 0.14%64K shares |
ALONGSIDE, LLC | 0.14%64K shares |
Cetera Investment Advisers | 0.13%55.94K shares |
SeaCrest Wealth Management, LLC | 0.11%50.1K shares |
KITCHING PARTNERS, LLC | 0.11%50K shares |
Integrated Wealth Concepts LLC | 0.09%40.01K shares |
PNC Financial Services Group, Inc. | 0.09%40K shares |
OSAIC HOLDINGS, INC. | 0.09%38.5K shares |
LPL Financial LLC | 0.08%36.38K shares |
StoneX Group Inc. | 0.05%23.26K shares |
MORGAN STANLEY | 0.05%22.57K shares |
Keel Point, LLC | 0.05%20.77K shares |
Percentages use 44.67M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data